CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses - Tateishi, Koichiro; Fujihashi, Kohtaro; Yamamoto, Norio; Hasegawa, Hideki; Ainai, Akira; Sato, Kayoko; Iho, Sumiko; Yamamoto, Saburo; Maeyama, Jun-ichi; Odagiri, Takato; Asanuma, Hideki (Vaccine, 2019)
Keywords: Adjuvant; Adjuvants; Allergy and Immunology; antibodies; Antigens; blood serum; Combined vaccines; CpG islands; CpG ODN G9.1; Experiments; Gene expression; IgA; IgG antibody; Immune response; Immune system; Immunoglobulin A; Immunoglobulin G; Infections; Infectious diseases; Inflammation; Influenza; influenza vaccines; Interferon; Lungs; mice; Mucosa; Nasal vaccination; nose; oligodeoxyribonucleotides; Oligonucleotides; Orthomyxoviridae; R&D; Research & development; Respiratory tract; vaccination; Vaccines; Viruses; United States--US; Japan; California; IgA; SRD; Nasal vaccination; PBMC; LD50; BSA; SD; Influenza; ODN; CpG ODN G9.1; Adjuvant; SEM; pfu; single radial immunodiffusion; plaque forming unit; LD 50; standard error of the mean; oligodeoxynucleotide; median lethal dose; peripheral blood mononuclear cell; bovine serum albumin; standard deviation